Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 432 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.31|
|52-week range||$4.42 - $18.00|
|50-day moving average||$5.87|
|200-day moving average||$8.11|
|Wall St. target price||$15.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.80|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-5.01%|
|1 month (2021-09-22)||-13.09%|
|3 months (2021-07-22)||-41.20%|
|6 months (2021-04-22)||-44.80%|
|1 year (2020-10-22)||-65.59%|
|2 years (2019-10-22)||-53.30%|
|3 years (2018-10-22)||11.99|
|5 years (2016-10-21)||8.59|
|Revenue TTM||$102.3 million|
|Gross profit TTM||$-45,433,000|
|Return on assets TTM||-34.8%|
|Return on equity TTM||-891.05%|
|Market capitalisation||$422 million|
TTM: trailing 12 months
There are currently 14.4 million Karyopharm Therapeutics shares held short by investors – that's known as Karyopharm Therapeutics's "short interest". This figure is 9.5% up from 13.2 million last month.
There are a few different ways that this level of interest in shorting Karyopharm Therapeutics shares can be evaluated.
Karyopharm Therapeutics's "short interest ratio" (SIR) is the quantity of Karyopharm Therapeutics shares currently shorted divided by the average quantity of Karyopharm Therapeutics shares traded daily (recently around 1.3 million). Karyopharm Therapeutics's SIR currently stands at 10.86. In other words for every 100,000 Karyopharm Therapeutics shares traded daily on the market, roughly 10860 shares are currently held short.
However Karyopharm Therapeutics's short interest can also be evaluated against the total number of Karyopharm Therapeutics shares, or, against the total number of tradable Karyopharm Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karyopharm Therapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Karyopharm Therapeutics shares in existence, roughly 190 shares are currently held short) or 0.2453% of the tradable shares (for every 100,000 tradable Karyopharm Therapeutics shares, roughly 245 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Karyopharm Therapeutics.
Find out more about how you can short Karyopharm Therapeutics stock.
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $4.42 up to $18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.1899. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U. S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.